孕期ADHD药物暴露与子代长期结局
基于丹麦全国登记库的队列研究纳入1998至2015年1068073名活产单胎,比较孕期继续与孕前停用ADHD药物的母亲子代,经Cox回归分析发现孕期ADHD药物暴露未增加子代神经发育精神障碍、视听损伤、癫痫、惊厥或生长障碍的风险。
要点
- 孕期继续ADHD药物与子代任何发育障碍综合风险无显著增加(aHR 0.97,95%CI 0.81-1.17)。
- 各亚类结局及阴性对照、同胞对照分析均未发现风险增加。
- 结果为依赖ADHD药物维持日常功能的孕妇继续用药提供 reassurance。
核心结论
- 孕期ADHD药物暴露与子代神经发育和生长结局无差异。
研究设计与样本
- 基于丹麦国家登记库的人群队列研究,纳入1998至2015年1068073名活产单胎,随访至发育诊断、死亡、移民或2018年12月31日。
- 比较孕期继续ADHD药物(哌甲酯、安非他明、右安非他明、赖氨酸安非他明、莫达非尼、托莫西汀、可乐定)的母亲子代与孕前停药母亲子代,采用Cox回归。
主要发现
- 898名儿童孕期暴露于ADHD药物,1270名儿童母亲孕前停药。
- 调整母亲人口学和精神病学特征后,任何子代发育障碍综合风险无增加(aHR 0.97,95%CI 0.81-1.17),各亚类亦无增加。
- 阴性对照和同胞对照分析中各亚类结局均无风险增加。
关键数值与推荐
- 主要结局为儿童或青少年期神经发育精神障碍、视听损伤、癫痫、惊厥或生长障碍。
临床怎么用
- 为依赖ADHD药物维持日常功能且考虑孕期继续用药的ADHD女性提供 reassurance。
局限性
- 暴露组样本量较小(898例),可能限制亚组分析效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. Concerns have been raised as to whether ADHD medication has long-term adverse effects on the offspring. The authors investigated whether in utero exposure to ADHD medication was associated with adverse long-term neurodevelopmental and growth outcomes in offspring. The population-based cohort study in the Danish national registers included 1,068,073 liveborn singletons from 1998 to 2015 followed until any developmental diagnosis, death, emigration, or December 31, 2018. Children of mothers who continued ADHD medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) during pregnancy and children of mothers who discontinued ADHD medication before pregnancy were compared using Cox regression. Main outcomes were neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment during childhood or adolescence. In total, 898 children were exposed to ADHD medication during pregnancy compared to 1270 children whose mothers discontinued ADHD medication before pregnancy. After adjustment for demographic and psychiatric characteristics of the mother, no increased risk of any offspring developmental disorders was found combined (aHR 0.97, 95% CI 0.81 to 1.17) or for separate subcategories. Similarly, no increased risk was found for any sub-categories of outcomes in the negative control or sibling controlled analyses. Neurodevelopment and growth in offspring do not differ based on antenatal exposure to ADHD medication. These findings provide reassurance for women with ADHD who depend on ADHD medication for daily functioning and who consider continuing medication in pregnancy.
引用
- Bang Madsen K, Robakis TK, Liu X, et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023. PMID: 36759544. doi:10.1038/s41380-023-01992-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。